摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 2-[(9S)-7-(4-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate | 1349067-91-9

中文名称
——
中文别名
——
英文名称
tert-butyl 2-[(9S)-7-(4-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
英文别名
——
tert-butyl 2-[(9S)-7-(4-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate化学式
CAS
1349067-91-9
化学式
C21H21ClN4O2S
mdl
——
分子量
428.942
InChiKey
NEGIVPOBHUUHCF-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    97.6
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
    申请人:BioTheryX, Inc.
    公开号:US20180170948A1
    公开(公告)日:2018-06-21
    The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
    本发明提供了调节蛋白功能的化合物,以恢复蛋白稳态,包括细胞因子、CK1α、GSPT1、艾奥洛斯和/或伊卡洛斯活性和细胞间粘附。该发明提供了一种调节蛋白介导的疾病的方法,如细胞因子介导的疾病、障碍、状况或反应。提供了包括与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防与蛋白相关的疾病、障碍或状况的方法,包括与细胞因子相关的疾病、障碍和状况,包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、屑病、屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
  • [EN] MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSITIONS CONTRACEPTIVES POUR LES HOMMES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    申请人:DANA FARBER CANCER INST INC
    公开号:WO2011143657A1
    公开(公告)日:2011-11-17
    The invention relates to compositions and methods for effecting male contraception.
    这项发明涉及用于实现男性避孕的组合物和方法。
  • [EN] COMPOSITIONS AND METHODS FOR MODULATING METABOLISM<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT DE MODULER UN MÉTABOLISME
    申请人:DANA FARBER CANCER INST INC
    公开号:WO2011143651A1
    公开(公告)日:2011-11-17
    The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.
    本发明提供了含有效量抑制BET蛋白(例如Brd2、Brd3、Brd4)的药物的组合物,以及使用这样的组合物治疗或预防代谢综合征、肥胖症、2型糖尿病、胰岛素抵抗和与代谢或脂肪积累不良变化相关的疾病的方法。
  • Thienotriazolodiazepine compounds for treating neoplasia
    申请人:Dana-Farber Cancer Institute, Inc.
    公开号:EP2902030A1
    公开(公告)日:2015-08-05
    The invention features compositions for treating or preventing a neoplasia. More specifically, the invention provides thienotriazolodiazepine compounds for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
    本发明的特征是用于治疗或预防肿瘤的组合物。更具体地说,本发明提供了噻吩三唑二氮杂卓化合物,用于破坏包含多聚酶链的 BET 家族多肽与染色质的相互作用(例如,破坏多聚酶链与存在于组蛋白 N 端尾巴上的乙酰-赖酸修饰的相互作用)。
  • Compositions and methods for treating neoplasia, inflammatory disease and other disorders
    申请人:Dana-Farber Cancer Institute, Inc.
    公开号:US10407441B2
    公开(公告)日:2019-09-10
    The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
    本发明的特点是治疗或预防肿瘤的组合物和方法。 更具体地说,本发明提供了破坏包含多聚酶链的 BET 家族多肽与染色质相互作用的组合物和方法(例如,破坏多聚酶链与存在于组蛋白 N 端尾上的乙酰-赖酸修饰的相互作用)。
查看更多

同类化合物

阿帕泛 贝帕泛 苯他西泮 环氯唑仑 溴替唑仑 氯噻西泮 司替帕泛 去甲氯噻西泮; 去甲基氯噻西泮; 5-(2-氯苯基)-7-乙基-1,3-二氢-2H-噻吩并[2,3-e][1,4]二氮杂卓-2-酮 伊拉帕泛 乙替唑仑 alpha-羟基依替唑仑 [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯 PROTACBET结合部分2 N-(4-叔-丁基苯基)-6-(2-氯苯基)-1-甲基-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲酰胺 7-氯-5-(2-氯苯基)-1,3-二氢-2H-噻吩并-(2,3-e)-(1,4)-二氮杂卓-2-硫酮 7-乙基-5-苯基-3,4-二氢噻吩并[3,2-f][1,4]二氮杂卓-2-酮 7-乙基-5-(2-氟苯基)-1,3-二氢-2H-噻吩并[2,3-e]-1,4-二氮杂卓-2-酮 6-(2-氯苯基)-1-甲基-N-[4-(三氟甲基)苯基]-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 6-(2-氯苯基)-1-甲基-N-(1-甲基-2-苯基乙基)-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 5-(2-氯苯基)-7-乙基-1H-噻吩并[2,3-e][1,4]二氮杂卓-2(3h)-硫酮 5-(2-氯苯基)-2,3-二氢-2-氧代-1H-噻吩并[2,3-e]-1,4-二氮杂卓-7-丙酸甲酯 5,6-二氢-5-甲基-6-氧代-4H-i咪唑并[1,5-a]噻吩并[2,3-f][1,4]二氮杂-3-羧酸1,1-二甲基乙酯 4-甲基-3,4-二氢-1H-噻吩并[2,3-E][1,4]二氮杂-2,5-二酮 4-(2-氯苯基)-N-(2-羟基乙基)-9-甲基-6H-噻吩并(3,2-f)(1,2,4)三唑并(4,3-a)(1,4)二氮杂卓-2-丙酰胺 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸甲酯 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸 4-(2-氯苯基)-9-甲基-2-(4-吗啉-4-基-4-羰基丁基)-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓 3-噻丁烷酮,2-氯-2-(1-甲基乙基)- 3-[4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-基]-2-丙炔-1-醇 2-((6R)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F]的[1,2,4 1H-噻吩并[2,3-e]-1,4-二氮杂卓-2,3-二酮,1-甲基-5-苯基-,3-肟 (S)-4-(4-氯苯基)-N-(4-羟基苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-乙酰胺 (S)-2-(5-(4-氯苯基)-6,7-二甲基-2-氧代-2,3-二氢-1H-噻吩并[2,3-E] (S)-2-(4-(4-氯苯基)-2-(羟甲基)-3,9-二甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3]-A][1,4]二氮杂卓-6-基)乙酸甲酯 (S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 (-)-JQ-1; (R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 (+)-JQ1羧酸 tetrahydro-furan-3-carboxylic acid [7-bromo-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-ylidene]-hydrazide 2-Bromo-4-(2-chloro-phenyl)-8-methyl-6H,8H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-9-one 4-(2-chloro-phenyl)-2-ethyl-9-oxo-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-8-carboxylic acid methylamide piperidine-4-carboxylic acid [7-bromo-5-(2-chloro-phenyl)-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-ylidene]-hydrazide 9-(2-chlorophenyl)-3-methyl-17-thia-2,4,5,8-tetrazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,11(16)-tetraene N,N-Diethyl-N'-thieno[3,2-b]pyrrolizin-(4Z)-ylidene-propane-1,3-diamine 2-bromo-4-(2-chloro-phenyl)-9-tetrahydrofuran-3-yl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 5-(2-chloro-phenyl)-1,6,7-trimethyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 4-(2-Chlorophenyl)-6H-thieno<3,2-f>-1,2,4-triazolo<4,3-a>-1,4-diazepine 4-(2-Chloro-phenyl)-9-cyclopropyl-2-iodo-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulene Acetic acid 5-(2-chloro-phenyl)-7-ethyl-2-oxo-2,3-dihydro-1H-thieno[2,3-e][1,4]diazepin-3-yl ester Acetic acid 5-(2-chloro-phenyl)-7-ethyl-1-methyl-2-oxo-2,3-dihydro-1H-thieno[2,3-e][1,4]diazepin-3-yl ester 2-ethyl-4-phenyl-6H-imidazo[1,2-a]thieno[3,2-f][1,4]diazepine